


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauR7MPS
Cm

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 261/20, 275/04, 413/12, 417/12	A1	(11) International Publication Number: WO 96/26929 (43) International Publication Date: 6 September 1996 (06.09.96)
(21) International Application Number: PCT/DK96/00084 (22) International Filing Date: 28 February 1996 (28.02.96) (30) Priority Data: 0207/95 28 February 1995 (28.02.95) DK (71) Applicant (for all designated States except US): H. LUND-BECK A/S [DK/DK]; Ootiliavej 9, DK-2500 Valby Copenhagen (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): FALCH, Erik [DK/DK]; Olgasvej 31, DK-2950 Vedbæk (DK). PERREGAARD, Jens, Kristian [DK/DK]; Thyraavej 22, DK-3620 Jægerspris (DK). SCHOUSBOE, Arne [DK/DK]; Steffensbjerg 5, DK-2750 Ballerup (DK). KROGSGAARD-LARSEN, Povl [DK/DK]; Elmevej 25, DK-3450 Allerød (DK). FRØLUND, Bente [DK/DK]; Landskronagade 61, 2.th., DK-2100 Copenhagen Ø (DK). MOLTZEN, Lenz, Sibylle [DK/DK]; Toftekarervej 29, DK-2820 Gentofte (DK). (74) Agent: MEIDAHN, PETERSEN, John; H. Lundbeck a/s, Ootiliavej 9, DK-2500 Valby Copenhagen (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: 4-AMINOTETRAHYDROBENZISOXAZOLE OR -ISOTHIAZOLE COMPOUNDS		
(Ia) (Ib)		
(57) Abstract 4-aminotetrahydrobenzisoxazole or -isothiazole compounds having general formulae (Ia) and (Ib), wherein R¹-R⁶, X and P are further defined in the description. The disclosed compounds have GABA (4-aminobutanoic acid) inhibiting activity and are useful in the treatment of analgesia, psychosis, convulsions, anxiety or muscular and movement disorders, especially epilepsy.		